Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole

NCT01615913 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Onychomycosis

Interventions

DRUG: 3 mg terbinafine and 2 mg ketoconazole containing patch
DRUG: 6 mg terbinafine and 2 mg ketoconazole containing patch
DRUG: 8 mg terbinafine and 2 mg ketoconazole containing patch

Sponsor

Taiwan Biotech Co., Ltd.